A regimen of inhaled Technosphere insulin and insulin degludec is just as good as usual care for glycaemic control, new evidence has indicated. During the study, the team of researchers from the ...

MONDAY, Dec. 16, 2024 (HealthDay News) -- For adults with type 1 diabetes, a regimen of inhaled Technosphere insulin (TI) plus insulin degludec is noninferior to usual care for glycemic control, ...

Once-weekly efsitora noninferior to once-daily degludec for decrease in mean glycated hemoglobin level. (HealthDay News) — Once-weekly efsitora is noninferior to once-daily degludec for reducing ...

Efsitora alfa vs degludec in adults with type 1 diabetics This 52-week Phase 3 trial (QWINT-5) aimed to assess the effectiveness and safety of efsitora compared with degludec in adults with type 1 ...

Results showed treatment with insulin efsitora was noninferior to insulin degludac based on reduction in HbA1c at 52 weeks. Once-weekly insulin efsitora was found to be as effective as daily basal ...

Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase 1 or phase 2 trials. We conducted a ...

In the phase 3 study, QWINT-1, efsitora was administered via four fixed doses once weekly in a single-use autoinjector in people with type 2 diabetes using basal insulin for the first time In a second ...

Over the course of 52 weeks, people with type 2 diabetes saw a greater average reduction in HbA1c with icodec compared with glargine U100 (estimated between-group difference -0.19%, 95% CI -0.36% to ...

Please provide your email address to receive an email when new articles are posted on . Women with type 1 diabetes who used insulin degludec during pregnancy had similar HbA1c and glucose profile as ...

Data presented today show more participants achieved greater treatment satisfaction when switching to once-weekly insulin icodec in ONWARDS 2 trial ‘Once-weekly insulin would be a remarkable step ...

Bagsværd, Denmark, 29 July 2022 - Novo Nordisk today announced headline results from the ONWARDS 3 and ONWARDS 4 phase 3a trials with once-weekly insulin icodec in adults with type 2 diabetes. ONWARDS ...

Bagsværd, Denmark,28 April 2022 - Novo Nordisk today announced headline results from the ONWARDS 2 trial, a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly ...